HOME > TOP STORIES
TOP STORIES
-
BUSINESS Meiji to Develop Lineup Unaffected by Price Revisions, Bolster Earnings from New Drugs/Generics in Focus Areas
July 12, 2023
-
REGULATORY MHLW Pharma Regulation Panel Kicks Off, Agrees to Discuss Incentives to Develop Pediatric Drugs
July 11, 2023
-
BUSINESS Shionogi to Cut 200 Jobs via Voluntary Buyout Program
July 11, 2023
-
ORGANIZATION Stop Requiring Japanese PI Data for Global Products: JPMA Officials
July 10, 2023
-
REGULATORY PMDA US Office to Set Out Solution for Drug Lag, Loss: Agency Chief
July 10, 2023
-
BUSINESS Full US Nod in Hand, Eisai CEO Keeps 1 Trillion Yen Sales Target for FY2030
July 10, 2023
-
BUSINESS FDA Awards Full Approval to Eisai’s Alzheimer’s Drug
July 7, 2023
-
REGULATORY Pharma Groups Float New Methods to Evaluate Innovative Drugs for 2024 Reform
July 6, 2023
-
REGULATORY Japan, US, Europe Trade Groups Urge Japan to Abolish “Spillover” Re-Pricing
July 6, 2023
-
BUSINESS Insmed Japan to Capitalize on Arikayce, Pins Hopes on Brensocatib: New President
July 5, 2023
-
BUSINESS Alarmed over Domestic Generics Biz, Sawai Group to Review Long-Term Targets
July 5, 2023
-
BUSINESS Jan Stefan Scheld to Helm Nippon Boehringer Ingelheim
July 5, 2023
-
BUSINESS Chugai Is Best-Paying Japan Pharma Again in FY2022, 5 Drug Makers Top 10 Million Yen
July 4, 2023
-
REGULATORY MHLW to Launch Pharma Affairs Study Group July 10, Drug Loss Up for Debate
July 4, 2023
-
REGULATORY LDP Bigwigs Launch Study Group on Drug Discovery to Spur Innovation
July 3, 2023
-
BUSINESS 32 Pharma Execs Take Home Over 100 Million Yen in FY2022, Top 3 from Takeda: Securities Reports
July 3, 2023
-
REGULATORY MHLW Expert Panel’s Report Serves as Starting Line for Reform: Asst. Vice Minister
June 30, 2023
-
REGULATORY Japan Mulls Narrowing Down COVID-19 Jabs to Pfizer, but Some Lawmakers Are Skeptical
June 29, 2023
-
BUSINESS Chugai Trims 150 Reps via Voluntary Buyout, Sales Force Down to 1,050 from July
June 29, 2023
-
REGULATORY MHLW Shuffles Senior Bureaucrats, Jo Tapped as Chief of Pharma Bureau
June 28, 2023
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
